7/5/2012 | CV | Market Commentary: Convertibles market quiet; Navistar steady before conference call; Patriot Coal around 30
|
7/3/2012 | CV | Market Commentary: Convertibles quiet ahead of holiday; Lincare, Theravance extend gains; U.S. Steel better
|
7/2/2012 | CV | Market Commentary: Lincare jumps on hedged basis on Linde takeout; Amylin up outright on Bristol-Myers deal
|
4/25/2012 | CV | Market Commentary: Iconix falls outright, flat to lower on hedge; Allegheny flat; Amylin up on lawsuit's end
|
4/23/2012 | CV | Market Commentary: Central European Distribution jumps on investment; Amylin up; James River Coal plunges
|
4/2/2012 | CV | Market Commentary: Convertibles flat to weaker: Gilead weaker, unchanged on hedge; James River down on hedge
|
3/30/2012 | CV | Market Commentary: Sino-Forest weaker on bankruptcy filing; United Rentals moves higher; Amylin extends gains
|
3/29/2012 | CV | Market Commentary: Omnicare active, holders make 5 points on exchange; Illumina adds on hedge; Amylin gains
|
3/28/2012 | CV | Market Commentary: Amylin adds on word of Bristol-Myers offer; Actuant down on hedge on call; Synnex mixed
|
3/28/2012 | CV | Amylin convertibles appear attractive in light of a potential Bristol-Myers takeover: Barclays
|
1/30/2012 | CV | Market Commentary: Amylin active; Theravance better bid; MF Global 'comes in'; RadioShack warns on earnings
|
1/27/2012 | CV | Market Commentary: Amylin shoots up on Bydureon clearance; Ford up ex-dividend; United Continental adds
|
11/8/2011 | CV | Market Commentary: Amylin sinks on severed Lilly alliance; Radian, DryShips improve; CEDC steady in trade
|
7/8/2011 | CV | Market Commentary: Convertibles quiet; Amylin adds 2 points on positive drug data; Kinetic up by 0.5 point
|
5/23/2011 | BK | Amylin draws $165 million under loan agreement with Eli Lilly
|
4/20/2011 | CV | Market Commentary: EMC gains on earnings; Textron slips on miss; Amgen up ahead of report; Amylin continues rally
|
4/18/2011 | BKCV | Amylin posts $475 mln cash at March 31, repays convertible in April
|
4/18/2011 | CV | Market Commentary: Convertibles weaken some; Amylin flat; Gilead mostly lower; A123 Systems sheds a point
|
4/15/2011 | CV | Market Commentary: New Sunrise Senior Living gains on debut; Amylin higher outright after positive drug news
|
3/4/2011 | CV | Market Commentary: NorthStar adds slightly on debut; Central European Distribution drops again; Old Republic lower
|
1/27/2011 | CV | Market Commentary: Amylin rises after earnings beat; ProLogis up outright, lower on hedge on merger talk
|
1/26/2011 | CV | Market Commentary: Nielsen trades higher on debut; Kodak drops on earnings miss; Hutchinson Technology steady
|
10/21/2010 | CV | Market Commentary: Cubist, Amylin in focus, unchanged in trade; Alliance Data, Covanta steady after earnings
|
10/20/2010 | CV | Market Commentary: New Cubist trades slightly over par; Amylin gets slammed but pares losses; Gilead quiet
|
6/29/2010 | SP | New Issue: Barclays prices $250,000 17.5% reverse convertibles linked to Amylin Pharmaceuticals
|
6/21/2010 | CV | Market Commentary: Biovail gains on merger with Valeant; Amgen up on competitor's drug safety; PPL on tap
|
6/18/2010 | CV | Market Commentary: Convertibles muted; Transocean rises; Amylin up on competitor's drug delay; Omnicom active
|
6/9/2010 | SP | Barclays to price 17.5% reverse convertibles linked to Amylin Pharmaceuticals
|
5/27/2010 | SP | New Issue: Barclays prices $1 million 19% reverse convertibles linked to Amylin Pharmaceuticals
|
5/11/2010 | SP | Barclays to price 19% reverse convertibles linked to Amylin Pharmaceuticals
|
4/29/2010 | SP | New Issue: Barclays prices $1 million 14.5% reverse convertibles linked to Amylin Pharmaceuticals
|
4/28/2010 | SP | New Issue: RBS prices $0.82 million 14% reverse convertibles linked to Amylin Pharmaceuticals
|
4/28/2010 | SP | New Issue: RBS prices $0.75 million 6.5% reverse convertibles linked to Amylin Pharmaceuticals
|
4/19/2010 | CV | Market Commentary: AMR, airlines extend losses on volcanic ash problem; Steel Dynamics dips ahead of earnings
|
4/16/2010 | CV | Market Commentary: Upsized MGM moves higher on debut; convertibles mostly quiet amid Goldman Sachs lawsuit
|
4/12/2010 | SP | Barclays to price 14.5% reverse convertibles linked to Amylin Pharmaceuticals
|
4/6/2010 | SP | RBS plans to price 14% reverse exchangeables linked to Amylin
|
3/16/2010 | SP | New Issue: RBS sells $90,000 15.5% reverse exchangeables linked to Amylin
|
3/15/2010 | CV | Market Commentary: Amylin gains with stock; Knight prices upsized deal at the middle of talk; Group 1 to price
|
3/11/2010 | CV | Market Commentary: International Coal trades up on debut; Hologic higher in active trade; Smithfield active
|
3/9/2010 | SP | New Issue: RBS sells $525,000 25% reverse exchangeables linked to Amylin stock
|
3/4/2010 | CV | Market Commentary: Priceline issue up in gray market; Take-Two expands; Amylin mostly steady after downgrade
|
3/3/2010 | SP | RBS plans to price 15.5% reverse convertibles linked to Amylin
|
3/1/2010 | CV | Market Commentary: Millipore a little weaker dollar neutral, but OSI Pharma expands; Amylin, Isis also in trade
|
2/26/2010 | CV | Market Commentary: Interpublic rises on earnings; NuVasive up on insurer support; Amylin gains with coverage
|
2/11/2010 | CV | Market Commentary: Newmont Mining up in trade; Equinix gains outright; Savvis lower; RadioShack rises to 112
|
1/26/2010 | CV | Market Commentary: Convertibles under pressure; EMC recoups; Amylin strengthens; Kinetic Concepts paper in trade
|
1/12/2010 | CV | Market Commentary: KKR trades up on debut; Salesforce.com bid fades in the gray; Hutchinson active; Amylin mixed
|
12/24/2009 | CV | Market Commentary: Convertibles quiet; Massey lower, but better dollar neutral; Micron, Navistar extend gains
|
12/23/2009 | CV | Market Commentary: Convertibles quiet; Micron extends gains; Transocean mixed; Amylin holds up as stock sinks
|
7/14/2009 | CV | Market Commentary: Convertibles strong: Kodak up; Amylin gains dollar neutral; miners active; Janus to price
|
6/10/2009 | SS | Amylin's board of directors now includes Icahn, Eastbourne nominees
|
6/5/2009 | SS | Market Commentary: Icahn burrows into Amylin, Biogen; NRG sets date for Exelon clash; Cougar buyout on track
|
5/27/2009 | SS | Market Commentary: Amylin gives up two board seats; AOL spinoff buzz increases; Cougar lacks counter bids
|
5/27/2009 | SS | Amylin, Eastbourne claim victory following company's annual meeting
|
5/20/2009 | SS | Amylin, Icahn, Eastbourne remain at odds over director nominees
|
5/18/2009 | SS | Amylin shareholder's slate garners support of proxy advisory firms
|
5/15/2009 | SS | Amylin dissidents get support of RiskMetrics for three nominees
|
5/14/2009 | SS | Icahn takes aim at Amylin's 'obfuscation' of facts in proxy contest
|
5/12/2009 | SS | Eastbourne asks Amylin shareholders to elect its three nominees
|
5/11/2009 | SS | Amylin continues to seek shareholder support for election on May 27
|
5/6/2009 | SS | Eastbourne continues to seek support ahead of Amylin election
|
5/1/2009 | SS | Amylin asks its shareholders to reject dissident slates on May 27
|
5/1/2009 | SS | Market Commentary: Amylin readies for proxy fight; Exelon should offer NRG more to save face, analyst says
|
4/24/2009 | SS | Amylin shareholder Eastbourne lacks confidence in company's board
|
4/23/2009 | SS | Icahn continues to push Amylin to allow talks, settle proxy contest
|
4/22/2009 | SS | Amylin, shareholders unable to reach settlement in proxy contest
|
4/22/2009 | SS | Market Commentary: Omnicare buyout rumors persist; analyst: abrupt Amylin sale unlikely; researchers drop Asyst
|
4/21/2009 | SS | Icahn clarifies statements made to Amylin lead director, chairman
|
4/20/2009 | SS | Amylin lead director accused of mischaracterizing Icahn's comments
|
4/15/2009 | CVSS | Amylin to approve, not recommend, dissident nominees to settle suit
|
4/15/2009 | SS | Icahn: Amylin's chairman is 'obvious choice' for first to leave board
|
4/15/2009 | SS | Market Commentary: Icahn's moves on Amylin watched closely; Validus bid for IPC a long shot, analyst says
|
4/3/2009 | CV | Market Commentary: Convertibles steady; Alcoa quiet but holds gains; Qwest Communications adds, but Amylin eases
|
4/3/2009 | SS | Eastbourne nominates five for election to Amylin board
|
4/2/2009 | CVSS | Amylin director says shareholder group lacks strategy, company moves on convertible, loan provisions
|
3/31/2009 | CV | Market Commentary: Teradyne, Ingersoll-Rand trade up in the gray; Alcoa gains in line; Alliant Techsystems weaker
|
3/31/2009 | SS | Market Commentary: IPC likely to stick with Max; Agrium may up CF bid to $85/share; Lilly, Amylin combo a distant dream
|
3/30/2009 | SS | Amylin shareholder plans five nominees, says poison put provisions 'threaten to tilt' playing field
|
3/30/2009 | SS | Market Commentary: CF may follow HudBay's path; Huntsman relies on bank suit; Amylin board fight offers no sale chance
|
3/9/2009 | SS | Amylin shareholder wants company to remove barriers to 'fair and unfettered' election
|
2/9/2009 | SS | Icahn's proposals take advantage of new North Dakota law that removes anti-takeover provisions
|
2/5/2009 | SS | Icahn boosts stake in Amylin Pharmaceuticals to 9.43%
|
2/2/2009 | SS | Amylin shareholder announces slate of five director nominees
|
2/2/2009 | SS | Market Commentary: Second Amylin shareholder wants changes; analysts predict higher bid for CV Therapeutics
|
1/30/2009 | SS | Amylin receives notice of further director nominations
|
1/29/2009 | SS | Icahn Partners to nominate five to Amylin Pharmaceuticals board
|
1/29/2009 | SS | Market Commentary: Whole Foods moves to settle with FTC; Amylin sale not expected in Icahn's wake; Wyeth shares fall
|
11/4/2008 | SS | Market Commentary: Amylin plunges 25.79%; Elliot cuts Epicor bid to $7.50; Merrill sets vote for Bank of America merger
|
11/3/2008 | SS | Shareholder to discuss options, including sale of company, with Amylin Pharmaceuticals
|
9/12/2008 | SS | Icahn boosts stake in Amylin Pharmaceuticals to 7.33%
|
8/29/2008 | SS | Amylin's standstill agreement with Eastbourne ends; shareholder may seek increased shareholder value
|
8/27/2008 | CV | Market Commentary: Amylin, Cell Genesys fall on product bombshells; Bristol-Myers stands pat; Fannie Mae extends gains
|
8/25/2008 | CV | Market Commentary: Ford drops to mid 60s amid higher oil; Suntech Power loses 0.5 point; Amylin trades with hopes for Byetta
|
8/18/2008 | CV | Market Commentary: Fannie Mae, Huntington edge lower; Amylin expands as shares sink; Cheniere places private deal
|
7/31/2008 | CV | Market Commentary: ImClone gains on Bristol-Myers offer; Amylin rises on M&A chatter; Hologic lower after earnings
|
6/9/2008 | CV | Market Commentary: Lehman trades mixed; CIT edges higher; Amylin quiet despite Byetta concerns, Bristow deal seen cheap
|
5/30/2008 | CV | Market Commentary: AIG gains on Morgan Stanley comments, other financials edge up; Transocean down; Penn Virginia jumps
|
5/22/2008 | SS | Icahn reports 6.54% ownership of Amylin Pharmaceuticals
|
10/30/2007 | SP | New Issue: Barclays prices $1 million 18.75% reverse convertibles linked to Amylin Pharmaceuticals
|
10/9/2007 | SP | Barclays to price 18.75% reverse convertibles linked to Amylin
|
8/17/2007 | CV | Market Commentary: Countrywide rebounds; Wild Oats rallies; Rare Hospitality skyrockets on takeover news
|
7/30/2007 | SP | New Issue: RBC sells $136,000 14.55% reverse convertibles linked to Amylin
|
7/30/2007 | SP | New Issue: RBC sells $642,000 13.4% reverse convertibles linked to Amylin
|
7/17/2007 | SP | RBC to price 14.55% reverse convertibles linked to Amylin
|
7/17/2007 | SP | RBC to price 13.4% reverse convertibles linked to Amylin
|
7/9/2007 | SP | New Issue: Barclays prices $1.5 million 14% reverse convertibles linked to Amylin
|
7/3/2007 | SP | Fortis to price 18.5% knock-in reverse convertibles linked to Amylin via LaSalle
|
6/22/2007 | SP | Barclays to price 14% reverse convertibles linked to Amylin Pharmaceuticals
|
6/19/2007 | SP | New Issue: Morgan Stanley prices $14.1 million 15.4% RevCons linked to Amylin
|
6/8/2007 | SP | Morgan Stanley moves back maturity of 15.4% RevCons linked to Amylin
|
6/5/2007 | CV | Market Commentary: Amylin gains on debut; Integra higher, Ciena, Dendreon quiet in gray; Cogent, Panda launch unusual deals
|
6/5/2007 | CV | New Issue: Amylin prices upsized $500 million seven-year convertibles at cheaps to yield 3%, up 40%
|
6/4/2007 | CV | Amylin narrows talk on upsized $500 million seven-year convertibles to 2.75%-3%, up 40%
|
6/4/2007 | CV | Market Commentary: Solectron surges on buyout; Amylin flat in gray; Dendreon faces borrow problem; Integra, Ciena plan deals
|
5/31/2007 | SP | Morgan Stanley to price 15.4% RevCons linked to Amylin
|
11/27/2006 | SS | Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
|
11/8/2006 | BT | Amylin gets neutral from Merrill
|
10/24/2006 | BT | Amylin: pipeline offers robust, sustainable opportunities beyond commercialized drugs
|
10/24/2006 | BT | Merrill keeps Amylin at neutral
|
10/19/2006 | BT | Merrill keeps Amylin at neutral
|
10/18/2006 | BT | Amlyin's Q3 product sales up 534% year over year, cash hits $832.55 million
|
10/17/2006 | BT | Amylin kept at outperform by Bear Stearns
|
10/17/2006 | BT | Amylin kept at outperform by Bear Stearns
|
10/2/2006 | BT | Amylin rated at neutral by Merrill
|
9/21/2006 | BT | Lilly, Amylin get recommendation from EMEA for diabetes treatment exenatide
|
9/14/2006 | BT | Eli Lilly, Amylin: exenatide as effective as NovoMix30 in controlling blood sugar
|
9/11/2006 | BT | Amylin says approval of Symlin/basel product would double drug's target audience
|
9/8/2006 | BT | Amylin kept at neutral by Merrill
|
9/7/2006 | BT | Amylin: Symlin improved diabetes control in type 2 patients
|
8/24/2006 | BTCV | Amylin Pharmaceuticals holders convert all 2.25% notes ahead of redemption
|
8/8/2006 | BT | Market Commentary: Barrier loses 13%; Teva up more than 5%; Antigenics comes off highs; Amylin falls 7%
|
7/25/2006 | BT | Merrill maintains Amylin at neutral
|
7/25/2006 | CV | Market Commentary: SanDisk jumps with strong earnings; Amylin in line after notes called; UAL prices $726 million deal
|
7/24/2006 | BTCV | Amylin Pharmaceuticals to call 2.25% convertibles due 2008
|
7/24/2006 | BT | Amylin second-quarter total revenues up at $118.1 million
|
7/24/2006 | CV | Market Commentary: Amazon.com better ahead of results; ImClone gains on buyout hopes; Amylin drops as call hurdle topples
|
7/21/2006 | BT | Amylin rated at neutral by Merrill
|
7/21/2006 | BT | Market Commentary: Amgen stronger; ReGen cheered; Cleveland BioLabs debuts lower; Amylin, Nektar weaker
|
7/17/2006 | CV | Market Commentary: Nabors falls with oil prices; Electronics for Imaging brightens with upgrade; Lucent still weak on forecasts
|
7/13/2006 | BT | Market Commentary: Nastech loses 15% on FDA snub; Novavax retreats; Anadys moves up; Acadia slumps; Illumina lifted
|
6/26/2006 | BT | Nastech, Amylin to develop nasal spray formulation of exenatide for diabetes
|
6/26/2006 | BT | Market Commentary: Vasogen plunges 74%; Anadys falls 45%; Nastech, Amylin gain on pact; Neurocrine finds buyers
|
6/23/2006 | BT | Amylin says it will be able to supply adequate quantities of Byetta by Q3
|
6/23/2006 | BT | Market Commentary: Neurocrine, DOV fall on Pfizer nixing indiplon funding; Endo rises 10%, Penwest gains 37%
|
6/14/2006 | BT | Merrill keeps Amylin at neutral
|
6/12/2006 | BT | Amylin, Eli Lilly: Byetta shown to reduce blood glucose levels when added to patients using thiazolidinedione
|
6/12/2006 | BT | Amylin, Lilly and Alkermes: study shows Byetta helps achieve glucose control in type 2 diabetes
|
6/12/2006 | BT | Amylin, Lilly: Two-year study shows Byetta sustains blood glucose control
|
6/12/2006 | BT | Amylin: Data show Leptin co-administration reduces body weight, body fat in animal studies
|
6/12/2006 | BT | Amylin kept at neutral by Merrill
|
6/1/2006 | BT | Amylin growing obesity program, plans human trials of novel compound this year
|
6/1/2006 | BT | Merrill Lynch comments on DPP-IV
|
5/18/2006 | BT | Amylin looks to increase Symlin, Byetta users by at least 2.7 million
|
4/27/2006 | BT | Merrill maintains Amylin at neutral
|
4/20/2006 | BT | Merrill maintains Amylin at neutral
|
4/11/2006 | CV | Market Commentary: Bausch and Lomb wider on product scare; Synaptics gains on iPod rumors; Medtronic plans $4 billion deal
|
4/4/2006 | BT | Amylin greenshoe exercised, raising follow-on stock sale to $534.75 million
|
3/30/2006 | BT | New Issue: Amylin raises $465 million in upsized follow-on of 10 million shares at $46.50 each
|
3/30/2006 | BT | Market Commentary: Amylin zooms to new high after follow-on; Seattle Genetics dips; Kosan declines 9% on spot sale
|
3/29/2006 | BT | Market Commentary: Amylin shares up ahead of deal; Idenix off despite Novartis aid; Antigenics, cancer names higher
|
3/28/2006 | BT | Market Commentary: Advanced Magnetics gains 7%; Xoma slides; Seattle Genetics deal surfaces; Cephalon dips 2%
|
3/27/2006 | BT | Amylin plans follow-on offering of 8.5 million shares via Morgan Stanley
|
3/27/2006 | BT | Amylin Pharmaceuticals files automatic shelf
|
3/27/2006 | BT | Merrill maintains Amylin at neutral
|
3/27/2006 | BT | Market Commentary: Amylin drops 3% on follow-on; Keryx up 3% on PIPE; Cubist off; Cephalon off, Generex dives 20%
|
3/2/2006 | BT | Merrill maintains Amylin at neutral
|
3/1/2006 | BT | Amylin, Eli Lilly submit supplemental NDA for diabetes drug Byetta
|
2/13/2006 | BT | Merrill moves Amylin to neutral
|
2/10/2006 | BT | Merrill maintains sell rating for Amylin
|
2/9/2006 | BT | Amylin's pramlintide produces more weight loss than diet and exercise alone, study says
|
2/9/2006 | BT | Market Commentary: Acorda IPO on deck with cheaper talk; Serono up on Glaxo chatter; Amylin soars; Charles River rises
|
1/30/2006 | BT | Market Commentary: Theravance at bat; Amylin dives; Nektar reverses; CV Therapeutics takes a hit; First Horizon higher
|
1/27/2006 | BT | Merrill keeps Amylin at sell
|
1/26/2006 | BT | Market Commentary: Altus rockets out of gate; Teva talk tightened; Alexion zooms; Amylin better; Cephalon gains; Nektar rises
|
1/10/2006 | BT | Amylin maintained by Merrill at sell
|
12/30/2005 | BT | Amylin buys Ohio facility, land for eventual manufacturing of exenatide LAR
|
12/12/2005 | BT | Amylin still rated sell by Merrill Lynch
|
12/1/2005 | BT | Merrill Lynch: Amylin still rated sell
|
11/28/2005 | BT | Market Commentary: Merck pressures biotech sector; Amgen, Genentech lead slide; Enzon, BioCryst, Pozen up a tad
|
11/28/2005 | BT | Amylin still sell, Merrill Lynch says
|
11/16/2005 | BT | Merrill Lynch keeps Amylin at sell rating
|
11/16/2005 | BT | Market Commentary: Gilead gains on Roche settlement; AtheroGenics sinks; Amylin rises
|
11/15/2005 | BT | Amylin Pharmaceuticals, Lilly announce positive results of Byetta for diabetes
|
11/2/2005 | BT | Market Commentary: Novavax stock slips 12.3% on $18 million direct placement; convertible biotech names mixed
|
10/28/2005 | CV | Market Commentary: Invitrogen drops, but gains on hedge; Amkor steadies after fall; Nektar weaker
|
10/27/2005 | BT | Merrill maintains Amylin at sell
|
10/27/2005 | BT | Market Commentary: NxStage soars on IPO debut; Durect launches equity deal; Cell Therapeutics deal abuzz; Amylin plunges
|
10/24/2005 | BT | Merrill Lynch maintains Amylin at sell
|
10/20/2005 | CV | Market Commentary: Convertibles market reverses course after strong start; Cypress pulled down; Amgen, biotechs weaker
|
10/3/2005 | BT | Amylin sales looking up as Biogen may face downside, Merrill report says
|
9/22/2005 | BT | Amylin maintained by Merrill Lynch at sell
|
9/2/2005 | BT | Market Commentary: Cell Therapeutics plunges on auditor departure; Amylin shares off on profit taking; Watson off
|
9/2/2005 | BT | Amylin downgraded to sell: Merrill
|
8/30/2005 | BT | New Issue: Amylin raises $152 million in follow-on at $31, discounted from $32.66 close
|
8/30/2005 | BT | Amylin maintained by Bear at outperform
|
8/30/2005 | BT | Market Commentary: Amylin loses 3% after follow-on; Manhattan Pharma taps PIPEs; Momenta sold on news; ViaCell off
|
8/29/2005 | CV | Market Commentary: GM trades mixed; Amylin extends gains; but Katrina contributes to quiet market, traders say
|
8/29/2005 | BT | Amylin dives on secondary sale of 5 million shares pitched at $30.50-$31.00 per share
|
8/29/2005 | BT | Market Commentary: AtheroGenics, Amylin Pharma, Alpharma extend gains on takeover chatter; Pfizer, Merck credit mixed
|
8/26/2005 | BT | Market Commentary: AtheroGenics joins Amylin in gains linked to takeover chatter; Isis easier; DOV Pharma dives
|
8/25/2005 | BT | Market Commentary: Nastech rises in face of follow-on deal; Amylin up on takeover buzz; Antigenics convertible finds buyers
|
8/25/2005 | CV | Market Commentary: GM, Ford convertibles trade mixed; Amylin rises; new Emdeon issue remains flat
|
8/23/2005 | CV | Market Commentary: Brocade convertibles move lower on call; Amylin gains outright but seen lower on a hedged basis
|
8/23/2005 | BT | Amylin reiterated by Merrill at neutral
|
8/23/2005 | BT | Market Commentary: Amylin stock, convertibles zoom on drug data; OSI rebounds; Merck credit finds buyers; Wyeth sold off
|
8/5/2005 | BT | Amylin estimates revised by Merrill Lynch
|
7/18/2005 | BT | Amylin maintained by Merrill Lynch at neutral
|
7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
7/1/2005 | BT | Market Commentary: Altana crushed by Pfizer news; Cubist, Corixa rise in thin market, Millennium off; Cephalon higher
|
6/14/2005 | BT | Market Commentary: Mylan tops biotech activity with big stock buyback; King issues eyed; Invitrogen convertible on tap
|
4/5/2004 | CV | Amylin greenshoe exercised, raising convertibles to $200 million
|
3/31/2004 | CV | New Issue: Amylin upsized $175 million convertible yields 2.5%, up 45%
|
3/31/2004 | CV | Market Commentary: Amylin at 102 bid before pricing aggressively; Caesars dips below par; Kerzner bets push past 101
|
3/30/2004 | CV | Amylin Pharma $150 million convertible talked at 2.5-3.0%, up 40-45%
|
3/30/2004 | CV | Market Commentary: Caesars, Kerzner, Impax Labs on tap with FelCor, Regal-Beloit; ON Semicon, Amylin launched
|
9/22/2003 | CV | Market Commentary: Motorola gains with stock on CEO departure; BioMarin steady after drug canceled
|
7/18/2003 | CV | Amylin greenshoe exercised, raising convertibles to $175 million
|
6/18/2003 | CV | New Issue: Amylin Pharmaceuticals $150 million convertibles yield 2.25%, up 33%
|
6/18/2003 | CV | Market Commentary: CNet pulled, other new deals sweetened; Reliant upsizes as buyers reach for a fat coupon
|
6/17/2003 | CV | Market Commentary: New deal parade marches on; Lattice reoffered at 98, still dives; secondary thin, lower
|
6/16/2003 | CV | Market Commentary: ICOS, Lattice at bat; buzz puts Nextel Partners eyeing another convert after new junk offering
|
6/16/2003 | CV | Amylin Pharmaceuticals $150 million convertibles talked to yield 1.25-1.75%, up 40-45%
|